Nirsevimab Shows Promise in Protecting Infants from RSV Lower Respiratory Tract Disease
A new study confirms that nirsevimab provides strong protection for infants against RSV-related lower respiratory tract disease, significantly reducing hospitalizations and healthcare visits during the RSV season.
Recent research published in the journal Pediatrics confirms that nirsevimab is highly effective in safeguarding infants against respiratory syncytial virus (RSV)-related lower respiratory tract disease (LRTD). The study, led by Dr. Amber Hsiao from the Kaiser Permanente Vaccine Study Center in Oakland, California, analyzed data from the 2023-2024 RSV season involving nearly 32,000 infants.
The research demonstrated that nearly half of these infants received nirsevimab, and among them, the incidence of RSV LRTD was significantly lower. Specifically, nirsevimab showed an effectiveness rate of 87.2% against RSV LRTD, 98% in preventing hospitalizations due to RSV LRTD, and 71% against PCR-confirmed RSV infections. Infants who received the medication experienced fewer healthcare encounters related to RSV and had substantially reduced odds of hospitalization.
These findings bolster the recommendations by the Advisory Committee on Immunization Practices, advocating for infants under 8 months to receive nirsevimab at the start of their first RSV season. The study underscores the potential of nirsevimab as a critical tool in reducing the burden of RSV illness in young children, providing further evidence of its role in pediatric preventive care.
For more details, the full study can be accessed through the DOI: 10.1542/peds.2024-069510.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative AI-Driven Spine Model Set to Revolutionize Lower Back Pain Treatment
A groundbreaking AI-powered spine modeling system is dramatically accelerating the creation of patient-specific lumbar spine models, promising to improve diagnosis, surgical planning, and personalized treatment for lower back pain.
Longer Residency in the U.S. Elevates Heart Disease Risk Among Immigrants
Research shows that immigrants to the U.S. initially have lower heart disease risk, but this advantage decreases the longer they reside in the country, highlighting the impact of lifestyle and environmental factors.
